Literature DB >> 17053980

Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype.

Nitin Kaila1, Robert J Straka, Richard C Brundage.   

Abstract

Mixture models are applied in population pharmacometrics to characterize underlying population distributions that are not adequately approximated by a single normal or lognormal distribution. In addition to obtaining individualized maximum a posteriori Bayesian post hoc parameter estimates, the subpopulation to which an individual was classified can be determined. However, the accuracy of the classification of subjects to subpopulations is not well studied. We investigated the impact of several factors on the accuracy of classification in mixture models applied to pharmacokinetics using a simulation strategy. The availability of actual subject data allowed us to evaluate mixture model classification in a potentially common application, namely, the classification of clearance into poor metabolizer (PM) or extensive metabolizer (EM) subgroups with the known phenotype status in subjects receiving metoprolol. The factors explored in the simulation study were the magnitude of difference between the clearances in two subpopulations, the between subject variability in clearance, the mixing-fraction, and the population sample size. Populations were simulated at various levels of the above factors and analyzed with a mixture model using NONMEM. The population pharmacokinetics of metoprolol were modeled with the EM/PM phenotype as a known covariate, and without the phenotype covariate using a mixture model. Within the range of scenarios studied, the proportion of subjects classified into the correct subpopulation was high. The simulation-estimation study suggests that a greater separation between two subpopulations, a smaller variability in the parameter distribution, a larger sample size, and a smaller size subpopulation tend to be associated with a greater accuracy of subpopulation classification when a mixture model is applied to pharmacokinetic data. In a population pharmacokinetic analysis of metoprolol, a drug that undergoes polymorphic metabolism, it was possible to correctly identify phenotype status using a mixture model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053980     DOI: 10.1007/s10928-006-9038-9

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  19 in total

Review 1.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

Authors:  D S Streetman; J S Bertino; A N Nafziger
Journal:  Pharmacogenetics       Date:  2000-04

2.  Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.

Authors:  S V Otton; H K Crewe; M S Lennard; G T Tucker; H F Woods
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

3.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

4.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.

Authors:  Issam Zineh; Amber L Beitelshees; Andrea Gaedigk; Joseph R Walker; Daniel F Pauly; Kathleen Eberst; J Steven Leeder; Michael S Phillips; Craig A Gelfand; Julie A Johnson
Journal:  Clin Pharmacol Ther       Date:  2004-12       Impact factor: 6.875

6.  Analysis of metoprolol enantiomers in human serum by liquid chromatography on a cellulose-based chiral stationary phase.

Authors:  R J Straka; K A Johnson; P S Marshall; R P Remmel
Journal:  J Chromatogr       Date:  1990-08-24

7.  Metoprolol metabolism via cytochrome P4502D6 in ethnic populations.

Authors:  J A Johnson; B S Burlew
Journal:  Drug Metab Dispos       Date:  1996-03       Impact factor: 3.922

8.  Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.

Authors:  Julia Kirchheiner; Claudia Heesch; Steffen Bauer; Christian Meisel; Angela Seringer; Mark Goldammer; Mladen Tzvetkov; Ingolf Meineke; Ivar Roots; Jürgen Brockmöller
Journal:  Clin Pharmacol Ther       Date:  2004-10       Impact factor: 6.875

9.  Evaluation of mixture modeling with count data using NONMEM.

Authors:  Bill Frame; Raymond Miller; Richard L Lalonde
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-06       Impact factor: 2.745

10.  Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.

Authors:  L J Schaaf; B R Dobbs; I R Edwards; D G Perrier
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more
  11 in total

1.  Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.

Authors:  Mahesh N Samtani; Nandini Raghavan; Yingqi Shi; Gerald Novak; Michael Farnum; Victor Lobanov; Tim Schultz; Eric Yang; Allitia DiBernardo; Vaibhav A Narayan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.

Authors:  Lu Gaohua; Khaled Abduljalil; Masoud Jamei; Trevor N Johnson; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

3.  Evaluation of Approaches to Deal with Low-Frequency Nuisance Covariates in Population Pharmacokinetic Analyses.

Authors:  Chakradhar V Lagishetty; Stephen B Duffull
Journal:  AAPS J       Date:  2015-06-26       Impact factor: 4.009

4.  Selecting cases for whom additional tests can improve prognostication.

Authors:  Xiaoqian Jiang; Jihoon Kim; Yuan Wu; Shuang Wang; Lucila Ohno-Machado
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

5.  Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations.

Authors:  Andy R Eugene
Journal:  Int J Clin Pharmacol Toxicol       Date:  2016-05-19

6.  Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.

Authors:  Eunice Yuen; Ivelina Gueorguieva; Stephen Wise; Danny Soon; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-26       Impact factor: 2.745

7.  Population Pharmacokinetic/Pharmacodyanamic Mixture Models via Maximum a Posteriori Estimation.

Authors:  Xiaoning Wang; Alan Schumitzky; David Z D'Argenio
Journal:  Comput Stat Data Anal       Date:  2009-10-01       Impact factor: 1.681

8.  Metoprolol Dose Equivalence in Adult Men and Women Based on Gender Differences: Pharmacokinetic Modeling and Simulations.

Authors:  Andy R Eugene
Journal:  Med Sci (Basel)       Date:  2016-11-15

9.  Development of visual predictive checks accounting for multimodal parameter distributions in mixture models.

Authors:  Usman Arshad; Estelle Chasseloup; Rikard Nordgren; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-09       Impact factor: 2.745

10.  Application of Deep Neural Networks as a Prescreening Tool to Assign Individualized Absorption Models in Pharmacokinetic Analysis.

Authors:  Mutaz M Jaber; Burhaneddin Yaman; Kyriakie Sarafoglou; Richard C Brundage
Journal:  Pharmaceutics       Date:  2021-05-26       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.